Abstract: HUTUDO1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods utilizing HUTUDO1 polypeptides and polynucleotides in diagnostic assays.

Abstract: A method and apparatus for personalizing information content for delivery to a requesting user is provided. With the method and apparatus, a set of actions needed to retrieve and organize requested content for a particular content request are selected and executed based on the concept of classifying the current situation, e.g., the requesting user attributes and the current system setting, along any number of predefined dimensions. The definition of what dimensions of classification there are and what distinctions are drawn during the process of classification is defined by the business application administrator. Once a classification definition is in place, it may be used and reused, along with other classifications, to be associated with actions that select the appropriate content.

Abstract: A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.

Abstract: The methods described herein provide for ways of modulating, specifically inhibiting, integrin activation. The methods include identifying compounds such as naturally occurring and non-naturally occurring polypeptides and small molecules which bind to the ?A domain of an integrin thus mimicking the contact between the CD loop with ?A domain. Contacting the ?A domain in this manner locks the integrin such that it is unable to be activated.

Abstract: Isoquinoline derivatives of the general formula (I) in which X, Y, Z, R1, R2 and n are as defined in Patent Claim (1), and physiologically acceptable salts or solvates thereof, are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammation, tumors, osteoporosis, infections and restenosis after angioplasty or in pathological processes which are maintained or propagated by angiogenesis.

Abstract: ERK-7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ERK-7 polypeptides and polynucleotides in diagnostic assays.

Abstract: A method of treating tumors, such as prostate tumors, breast tumors, non-Hodgkin's lymphoma, and the like, includes the sequential steps of administering to the patient at least one dose of an antiangiogenic cyclo-arginine-glycine-aspartic acid-containing pentapeptide (cRGD pentapeptide); administering to the patient an anti-tumor effective amount of a radioimmunotherapeutic agent (RIT); and then administering to the patient at least one additional dose of cRGD pentapeptide. The cRGD pentapeptide is preferably cyclo-(Arg-Gly-Asp-D-Phe-[N-Me]-Val), and the RIT is preferably a radionuclide-labeled chelating agent-ligand complex in which chelating agent is chemically bonded to a tumor-targeting molecule, such as a monoclonal antibody.

Abstract: Novel biphenyl derivatives of the general formula I in which R1, R1?, R1?, R2, R2?, R3 and n are as defined in Patent claim 1, stereoisomers thereof and physiologically acceptable salts or solvates thereof are novel integrin inhibitors which preferentially inhibit the ?v?6 integrin receptor. The novel compounds can be used, in particular, as medicaments.

Abstract: The invention relates to a novel purified recombinant ?V?3 adhesion receptor which shows an unimpaired ligand binding activity, and a process for preparing said soluble non-membrane bound receptor in excellent yields by recombinant techniques using a baculovirus-insect cell expression system. The so-synthesized soluble receptor may be used very easily as screening tool for new therapeutic compounds which may inhibit the natural ?v?3 adhesion receptor. Such therapeutic compounds which can be discovered very easily, fast and without health risk by means of the souluble receptors according to the invention may be, for example, RGD peptides or non-peptidic compounds mimicking the natural ligand epitopes. The invention relates, furthermore, to a corresponding process for preparing recombinant full-length ?V?3 adhesion receptor in excellent yields, additionally using detergents to dissolve the membrane bound receptor from the surface of the host cell.

Abstract: Isoquinoline derivatives of the general formula (I) in which X, Y, Z, R1, R2, and n are as defined in Patent Claim (1), and physiologically acceptable salts or solvates thereof, are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammation, tumours, osteoporosis, infections and restenosis after angioplasty or in pathological processes which are maintained or propagated by angiogenesis.

Abstract: The invention relates to compounds having formula (I), wherein R1, R2, R3, R4, R5, R7, R8, R11, Z, m and n have the meaning cited in claim 1, and to the physiologically acceptable salts and solvates which can be used as integrin inhibitors, especially in the prophylaxis and treatment of circulatory diseases, in case of thrombosis, myocardial infarction, coronary heart diseases, arteriosclerosis, osteoporosis, pathologic processes caused or propagated by angiogenesis and in tumor therapy.

Abstract: A method and apparatus for distributed computing in a network data processing system. A task is accepted for distributed computing. Work units are sent to a plurality of data processing systems on a network, wherein each data processing system within the plurality of data processing systems includes a software for accepting a work unit, processing the work unit to generate a result, and returning the result, wherein the software is monitored for compliance with an operation policy requiring a connection to the network and allocating a period of time for processing work units. Results are received from the plurality of data processing systems. These data processing systems may be individually owned by consumers in which the systems are provided at no cost or some lower cost in return for making available processing resources for processing work units.

Abstract: ERK-7 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing ERK-7 polypeptides and polynucleotides in diagnostic assays.

Abstract: Novel biphenyl derivatives of the general formula (I), in which A, X, R1, R1′, R1″, R2 R2′, R2″ and n are as defined in Patent claim 1, stereoisomers thereof and physiologically acceptable salts or solvates thereof are novel inhibitors of integrin receptors, in particular of the &agr;v&bgr;3, &agr;v&bgr;5 and/or &agr;v&bgr;6 integrin receptors. The novel compounds can be used as medicaments.

Abstract: Novel biphenyl derivatives of the general formula I 1

Abstract: Indol-3-yl derivatives of the general formula I 1

Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) orchemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.

Abstract: HUTUDO1 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods utilizing HUTUDO1 polypeptides and polynucleotides in diagnostic assays.

Abstract: Indol-3-yl derivatives of the general formula I in which A, B, X, R1, R2, R3, R4, R5, n and m are as defined in patent claim 1, and their physiologically acceptable salts or solvates are integrin inhibitors and can be employed for combating thromboses, cardiac infarction, coronary heart diseases, arteriosclerosis, inflammations, tumours, osteoporosis, rheumatic arthritis, macular degenerative disease, diabetic retinopathy, infections and restenosis after angioplasty or in pathological processes maintained or propagated by angiogenesis.

Abstract: Human sprouty-4 orthologue polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing human sprouty-4 orthologue polypeptides and polynucleotides in diagnostic assays.